Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrolife AB's revenue for the
three
months ended in Jun. 2026 was kr857 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was kr3,390 Mil.
Vitrolife AB's Revenue per Share for the
three
months ended in Jun. 2026 was kr6.33.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was kr25.03.
Warning Sign:
Vitrolife AB revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Vitrolife AB was -4.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 2.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 18.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 15.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Vitrolife AB's highest 3-Year average Revenue per Share Growth Rate was 31.20% per year. The lowest was 2.10% per year. And the median was 17.50% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Vitrolife AB Revenue Related Terms
Vitrolife AB Revenue Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Vitrolife AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Revenue distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr3,390 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrolife AB (CHIX:VITRS) has a Revenue of kr3,390 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Vitrolife AB and its competitors.
Is Vitrolife AB's Revenue too high?
Vitrolife AB's current Revenue is kr3,390 Mil. Overall, Vitrolife AB has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Revenue compare to ABT and SYK?
Vitrolife AB's Revenue of kr3,390 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Vitrolife AB and its competitors. Vitrolife AB's current Revenue is kr3,390 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Vitrolife AB (CHIX:VITRS) has a current Revenue of kr3,390 Mil. The stock's GF Value™ is kr185.92, compared to a current price of kr86.38 — trading 53.5% below its estimated fair value. The current Revenue is kr3,390 Mil. Vitrolife AB's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current Revenue is kr3,390 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr86.38 is trading 53.5% below its estimated GF Value™ of kr185.92.
Key valuation signals for CHIX:VITRS:
Revenue: kr3,390 Mil
GF Value™: kr185.92 vs. price of kr86.38 (53.5% below fair value)
No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
80GF Score
Get the complete analysis for CHIX:VITRS
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VITRS has been successfully added to your 
